Dahlak Daniel Solomon

Dr. Dahlak Daniel Solomon


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Methods
Verified
Journal Article
Closed access
CWChih-Yang Wang
Chih-Yang Wang
CKChing-Chung Ko
Ching-Chung Ko
SKSachin Kumar
Sachin Kumar
DXDo Thi Minh Xuan
Do Thi Minh Xuan
HLHui-Ru Lin
Hui-Ru Lin
DSDahlak Daniel Solomon
Dahlak Daniel Solomon

11 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SKSachin Kumar
Sachin Kumar
Chih-Yang WangChih-Yang Wang
Chih-Yang Wang
HLHelena Kishore Lalwani
Helena Kishore Lalwani
JNJuan Lorell Ngadio
Juan Lorell Ngadio
FWFitria Sari Wulandari
Fitria Sari Wulandari
HLHui-Pu Liu
Hui-Pu Liu
Background/Objectives: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and remains associated with poor prognosis despite multimodal therapy. Metabolic reprogramming, particularly increased dependence on glutamine, supports GBM bioenergetic, biosynthetic, and redox demands. This study aimed to systematically identify glutamine-associated metabolic regulators with prognostic relevance and biological plausibility in GBM. Methods: Transcriptomic data from TCGA and GTEx were analyzed using GEPIA2, with survival validation performed using the CGGA. Functional pathway enrichment, protein expression assessment, protein–protein interaction network analysis, tumor microenvironment evaluation, epigenetic profiling, and single-cell RNA sequencing validation were integrated to contextualize candidate genes. Pharmacogenomic correlation analysis and structure-based molecular docking were applied as supportive validation layers. Results: Ceruloplasmin (CP), Solute Carrier Family 25 Member 13 (SLC25A13), and Solute Carrier Family 38 Member 2 (SLC38A2) were selectively dysregulated and associated with poor clinical outcomes in GBM. CP was linked to redox regulation and stress-adaptive survival programs, SLC25A13 to mitochondrial metabolite exchange and glutamine-coupled nucleotide biosynthesis, and SLC38A2 to glutamine uptake, nutrient sensing, and mTORC1-MYC-associated growth signaling. Conclusions: CP, SLC25A13, and SLC38A2 emerge as clinically relevant glutamine-associated metabolic regulators in GBM, linking redox regulation, mitochondrial metabolite exchange, and glutamine-driven growth signaling. These findings highlight transport- and exchange-centered metabolic nodes as potential biomarkers and candidates for future metabolic targeting in GBM.

8 August 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
CLChan-Chuan Liu
Chan-Chuan Liu
CWCheng-Lin Wu
Cheng-Lin Wu
Chih-Yang WangChih-Yang Wang
Chih-Yang Wang
JLJung-Shun Lee
Jung-Shun Lee
PCPin-Yuan Chen
Pin-Yuan Chen
KCKwang-Yu Chang
Kwang-Yu Chang
Glioblastoma (GBM) is an incurable brain tumor with poor survival outcomes. Its progression and recurrence are strongly influenced by infiltrative growth o

12 August 2026 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
HLHui-Pu Liu
Hui-Pu Liu
ITI-Hao Tseng
I-Hao Tseng
CHChung-Bao Hsieh
Chung-Bao Hsieh
YWYa-Chun Wu
Ya-Chun Wu
KCKai-Fu Chang
Kai-Fu Chang
PCPo-Kai Chuang
Po-Kai Chuang
Galectin-3 (LGALS3), a β-galactoside-binding lectin, plays a pivotal role in regulating physiological and pathological processes in hepatocellular car